Please login to the form below

Not currently logged in
Email:
Password:

Immune Therapeutics

This page shows the latest Immune Therapeutics news and features for those working in and with pharma, biotech and healthcare.

Amgen pledges $1.5bn for CytomX preclinical cancer drugs

Amgen pledges $1.5bn for CytomX preclinical cancer drugs

engaging antibody programme still in early-stage development at CytomX Therapeutics. ... Amgen is not the first big biopharma company to be impressed by CytomX’s Probody therapeutics, which are designed to direct immune T cells to cancer cells, while

Latest news

  • Sanofi and Ablynx sign €2.4bn nanobody deal Sanofi and Ablynx sign €2.4bn nanobody deal

    The partners will focus on developing and commercialising nanobody-based therapeutics for the treatment of various immune-mediated inflammatory diseases (IMID). ... a world-leader like Sanofi in the development of a new generation of therapeutics for the

  • Dutch companies partner on vaccines

    Pepscan focuses on protein mimicking technology for the generation of immune therapeutics.

  • Potential blood cancer treatment tested

    Immune System Therapeutics has launched a clinical trial to test its breakthrough treatment for terminal blood cancers. ... Immune System Therapeutics Ltd (IST) has launched a clinical trial to test its breakthrough treatment for terminal blood cancers.

  • Pfizer to acquire Coley Pharmaceutical

    Coley's portfolio includes a new class of drug candidates called TLR Therapeutics which stimulate or block immune system Toll-like receptors (TLRs). ... advancing TLR Therapeutic candidates that may be capable of directing the immune system to treat a

  • Forging ahead

    Positive results from ongoing phase II trials of Trinam, Ark Therapeutics' novel gene therapy to prevent blood vessels blocking in kidney dialysis patients who have undergone vascular access graft surgery, were ... Shares in biopharmaceutical company

More from news
Approximately 0 fully matching, plus 6 partially matching documents found.

Latest Intelligence

  • Deal Watch July 2016 Deal Watch July 2016

    Jounce Therapeutics/ Celgene. Portfolio and platform of biomarker driven immuno-oncology therapeutics and CDx. ... Licence. 1, 115. Sorrento Therapeutics/ Servier. STI-A1110 - anti-PD1 immune checkpoint mAb.

  • Pharma deals during September 2012 Pharma deals during September 2012

    Baxter International has been granted a licence for commercialisation rights for Estybon (rigosertib) in Europe by Onconova Therapeutics. ... Lebanese company Immunext is developing novel therapeutics that modulate the immune system to treat cancer, and

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest appointments

  • Gamida Cell strengthens leadership team Gamida Cell strengthens leadership team

    Appoints Josh Hamermesh and Paul Nee. Cellular and immune therapeutics group Gamida Cell has appointed a new chief business officer in the form of Josh Hamermesh.

  • Scancell appoints Dr Cliff Holloway as CEO Scancell appoints Dr Cliff Holloway as CEO

    Prior to this, he was chief executive officer and managing director of Sienna Cancer Diagnostics, and has held roles for Immune System Therapeutics and Biosceptre International. ... John Chiplin, executive chairman, Scancell, said: “Cliff’s extensive

  • Ex J&J VP joins board of Immune Ex J&J VP joins board of Immune

    Cameron Durrant also has senior experience at Pharmacia. Immune Pharmaceuticals has added veteran pharma experience to its board with the appointment of Cameron Durrant. ... Immune specialises in developing antibodies to treat patients with inflammatory

More from appointments
Approximately 1 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Blue Latitude Health

Blue Latitude Health is a creative marketing consultancy. Founded in 2003, our combination of heritage, approach and capability gives us...

Latest intelligence

The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again - in exchange for uptake promises...
Digital applications are transforming the market access landscape
Organisations are leveraging new technology to implement a wider range of business models and, in essence, drive market access success by working smarter, faster and with greater economy....
Escaping the spin cycle of sub-optimal launch
...

Infographics